Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-24-007096

← back to feed
Filed
Feb 20, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Feb 20, 2024 67.47M sh
Cash And Equivalents Q2 2024 · Dec 31, 2023 $2.62K
Cash And Equivalents Q2 2024 · Jun 30, 2023 $35.15K
Current Liabilities Q2 2024 · Dec 31, 2023 $316.81K
Current Liabilities Q2 2024 · Jun 30, 2023 $295.13K
Total Liabilities Q2 2024 · Dec 31, 2023 $316.81K
Total Liabilities Q2 2024 · Jun 30, 2023 $295.13K
Current Assets Q2 2024 · Dec 31, 2023 $2.62K
Current Assets Q2 2024 · Jun 30, 2023 $43.13K
Total Assets Q2 2024 · Dec 31, 2023 $2.62K
Total Assets Q2 2024 · Jun 30, 2023 $43.13K
Operating Income Q2 2024 · Dec 31, 2023 $11.39M
Shares Diluted Q2 2024 · Dec 31, 2022 61.92M sh
Shares Diluted Q2 2024 · Dec 31, 2022 61.49M sh
Operating Cash Flow Q2 2024 · Dec 31, 2022 −$47.91K
Stockholders Equity Q2 2024 · Dec 31, 2022 −$202.32K
Stockholders Equity Q2 2024 · Sep 30, 2022 −$160.6K
Stockholders Equity Q2 2024 · Jun 30, 2022 −$117.61K
Eps Diluted Q2 2024 · Dec 31, 2022 $0.00
Eps Diluted Q2 2024 · Dec 31, 2022 $0.00
Eps Basic Q2 2024 · Dec 31, 2022 $0.00
Eps Basic Q2 2024 · Dec 31, 2022 $0.00
Sga Expense Q2 2024 · Dec 31, 2022 $66.87K
Sga Expense Q2 2024 · Dec 31, 2022 $125.93K
Rd Expense Q2 2024 · Dec 31, 2022 $0
Net Income Q2 2024 · Dec 31, 2022 −$93.59K
Net Income Q2 2024 · Dec 31, 2022 −$188.47K
Net Income Q2 2024 · Sep 30, 2022 −$94.87K